5 funding - 839,861€

data available since 2018

2021

  1. DELETE. ImproveD procEdural workfLow for cathETEr ablation

    euro 202,660.00

  2. COMBATBIL

    euro 150,682.00

2020

  1. GSK BIOBADALER

    euro 173,880.00

  2. Estudio piloto para evaluar el potencial uso de la ivermecti

    euro 37,239.00

2018

  1. Phase I- II Study of intratumoral urelumab combined with niv

    euro 275,400.00